Metathesis Platform Licensed to Aileron Therapeutics

Materia, Inc., a catalyst technology company, announced today the licensing of its metathesis platform to Aileron Therapeutics, an emerging biopharmaceutical company...

PASADENA, CA. – (BusinessWire) – February 12, 2007. Materia, Inc., a catalyst technology company, announced today the licensing of its metathesis platform to Aileron Therapeutics, an emerging biopharmaceutical company, for use in the discovery and development of peptide therapeutics directed at intracellular protein-protein interaction targets. As consideration for the license, Materia will receive license fees, milestone payments, and royalties.

Metathesis catalysts enable the formation and manipulation of carbon-carbon bonds in the synthesis of entirely new biopharmaceutical products with superior properties as well as in the development of new, more efficient and low cost production processes for existing products. Materia’s catalysts include those from Professor Robert Grubbs at Caltech who won the Nobel Prize for the technology in 2005.

“Aileron has taken a novel approach towards the design of pharmaceutically-active biologics and we support these efforts,” stated Dr. Michael Giardello, Materia’s Chief Executive Officer. “This work further demonstrates the breadth of application for Materia’s metathesis catalyst platform.”

“Materia is the leader in olefin metathesis technology, and we are pleased to have such a distinguished partner that brings the kind of unique expertise that will accelerate our efforts to create a new class of peptide therapeutics,” stated Joseph Yanchik, Aileron’s Chief Executive Officer.

About Materia

Materia was founded in 1998 to commercialize olefin metathesis catalyst technology. This market-enabling, Nobel Prize winning, green chemical technology enables chemical compounds to be synthesized with greater efficiency, under less stringent reaction conditions, and with reduced byproducts and hazardous waste. As stated by the Royal Swedish Academy of Sciences when awarding the 2005 Nobel Prize, “metathesis is an example of how important basic science has been applied for the benefit of man, society, and the environment.” For more information, visit: www.materia-inc.com.

About Aileron

Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeutics for the treatment of cancer and other intractable diseases. Aileron’s technology is the first and only process that allows peptides to penetrate cells in a sequence-independent manner. Aileron is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by small molecule or biological drugs. For more information, visit: www.aileronrx.com